Goldman Sachs tips CSL share price to climb to $223.00

The CSL Limited (ASX:CSL) share price could keep climbing higher according to Goldman Sachs…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ahead of its Global Healthcare Conference in the United States, this morning Goldman Sachs took a deep dive into its forecasts and target prices across its Australian healthcare coverage.

One company that came out of its review favourably was CSL Limited (ASX: CSL). According to the note, CSL remains the broker's top pick in the local healthcare sector and has increased its target price to $223.00.

This implies potential upside of around 9.4% from its last close price.

Why does Goldman Sachs rate CSL as a buy?

One reason Goldman is bullish on CSL is that it believes the strength the biotechnology giant is experiencing in Immunoglobulins outweighs operational risks.

The broker notes that the Immunoglobulins business is accelerating as its legacy products wind down. Further, recent industry feedback is consistently positive on the near/mid-term trajectory of Immunoglobulins.

In light of this, Goldman has "forecast double digit 3-year CAGRs for both Privigen (+10%) and Hizentra (+13%), driven by improved awareness/diagnosis and a positive shift onto the neurological indication, CIDP."

In addition, the broker notes that the current pricing environment is supportive and expects it to contribute to a stable gross margin development across the Behring business "despite the real threat from accelerating donor fee inflation and last litre."

Another reason to be positive is the company's Speciality products. Goldman has been positively surprised at the performance of this side of the business.

"Although Takhzyro (lanadelumab) is now widely available, Haegarda continues to take new patient starts in all markets in which it has launched. We continue to assume a distinct minority of new starts but relative stickiness in existing share."

Overall, the broker believes CSL is well-placed to grow its earnings per share at a strong rate through to at least FY 2021.

What about its peers?

The broker also reiterated its buy rating on Cochlear Limited (ASX: COH) and increased the price target on the hearing solutions company's shares to $209.00.

However, Goldman remains bearish on Ramsay Health Care Limited (ASX: RHC) and has once again rated its shares as a sell, albeit with an improved price target of $57.00. The broker has concerns over the decline in private health insurance participation rates and cost inflation, particularly with nurse wages.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »

A woman puts her hands up as she smashes and breaks through a glass ceiling.
Share Gainers

How these 5 ASX 200 stocks are smashing the benchmark this week

These fives ASX 200 stocks have made some very happy shareholders this week. Here’s how.

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Catalyst Metals, Duratec, Nufarm, and Rio Tinto shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A smiling woman at a hardware shop selects paint colours from a wall display.
Broker Notes

After its strategy day, what does Macquarie think Wesfarmers shares are worth?

Let's see what the broker is saying about this blue chip.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Technology Shares

After surging 13% yesterday, are TechnologyOne shares a buy, hold or sell according to Macquarie?

Valuations matter when investing, and Macquarie feels no different.

Read more »